deferasirox has been researched along with 8-hydroxy-2'-deoxyguanosine in 1 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (8-hydroxy-2'-deoxyguanosine) | Trials (8-hydroxy-2'-deoxyguanosine) | Recent Studies (post-2010) (8-hydroxy-2'-deoxyguanosine) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 4,821 | 238 | 2,164 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, T; Iyama, S; Kaneko, Y; Kato, J; Kawano, Y; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Ono, K; Sato, T; Sato, Y; Takada, K; Takimoto, R | 1 |
1 other study(ies) available for deferasirox and 8-hydroxy-2'-deoxyguanosine
| Article | Year |
|---|---|
Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antigens, CD; Benzoates; Case-Control Studies; Deferasirox; Deoxyguanosine; DNA Damage; Erythrocyte Transfusion; Ferritins; Genome, Human; Humans; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Prospective Studies; Reactive Oxygen Species; Statistics, Nonparametric; Triazoles | 2012 |